The risk of therapy duplication with OTC and prescription PPIs can be lowered with an innovative, multi-faceted, and intentional approach by pharmacy teams and prescribers.
Khemraj Hirani, PhD, RPh, MBA, MPharm, RAC, CIP, CCRP
Advertisement
Articles by Khemraj Hirani, PhD, RPh, MBA, MPharm, RAC, CIP, CCRP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
FDA Approves Imlunestrant Tablets for ER+, HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer
2
IMWG Consensus Risk Criteria Predicts Survival in Daratumumab Quadruplet Therapy
3
Linvoseltamab Monotherapy Elicits Promising ORR, MRD-Negativity in NDMM
4
How Pharmacists Support CDK4/6 Inhibitor Management and Patient Care
5
